Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.36 AUD
Change Today +0.01 / 2.86%
Volume 24.2K
As of 10:55 PM 10/4/15 All times are local (Market data is delayed by at least 15 minutes).

idt australia ltd (IDT) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/24/15 - A$0.42
52 Week Low
02/17/15 - A$0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IDT AUSTRALIA LTD (IDT)

Related News

No related news articles were found.

idt australia ltd (IDT) Related Businessweek News

No Related Businessweek News Found

idt australia ltd (IDT) Details

IDT Australia Limited provides products, research and development, and other technical services for the pharmaceutical and allied industries in Australia. It is involved in the development, scale-up, and manufacture of high potency and cytotoxic API, and finished drug products. The company develops cytotoxics, anti-cancer drugs, anti-psychotics, antibiotics, beta lactams, and controlled drugs. It also offers various specialist clinical trial labelling, packaging, and dispensing services; and clinical trials research and pharmacy services in a range of therapeutic areas. In addition, the company manufactures active and placebo clinical trial supplies in various dosage forms, such as tablets, coated tablets, capsules, suspensions, liquids, sprays, patches, lyophilised powders, and ointments. Further, it offers analytical services, such as method validation/verification, compendial testing, stability testing, microbiology testing, cleaning validation, identity testing, assembly, related substances, residual solvents, limit testing, melting point, clarity, gravimetric, viscosity, dissolution, dosage uniformity, hardness/friability/disintegration, and chemical monitoring services. IDT Australia Limited is headquartered in Boronia, Australia.

idt australia ltd (IDT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$355.7K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$193.5K
Vice President of Legal & Corporate Developme...
Total Annual Compensation: A$246.5K
Vice President of Clinical Services and Gener...
Total Annual Compensation: A$180.6K
Compensation as of Fiscal Year 2015.

idt australia ltd (IDT) Key Developments

IDT Australia Limited Reports Earnings Results for the Year Ended June 30, 2015

IDT Australia Limited reported earnings results for the year ended June 30, 2015. For the year, the company’s revenue was AUD 15.7 million against AUD 13.2 million a year ago. This improvement was driven by a 55% improvement in second half revenues against the first 6 months, from AUD 6.1 million in the first half to AUD 9.6 million in the second half. Operating loss after tax was AUD 3.0 million against AUD 6.6 million a year ago. Containment of operating expenses and no impairment of development assets saw the loss for the full year after income tax reduce by AUD 3.6 million to AUD 3.0 million, with a small profit after tax generated in the second half.

IDT Australia Limited and ANI Pharmaceuticals Inc Enters into Marketing and Distribution Agreement

IDT Australia Ltd. will get ANI Pharmaceuticals Inc. to market and distribute in the US up to 18 of IDT's recently acquired generic pharmaceutical products. Under the agreement ANI makes an upfront payment of $1 million to IDT for exclusive rights to commercialise the products in the US market. Launch milestones of up to a further $1.25 million will also be payable as the products come back on market.

IDT Australia Limited Appoints Alan Fisher to the Board

IDT Australia Limited announced that Mr. Alan Fisher has been appointed to the IDT Board. His appointment is effective June 10, 2015. Alan has extensive business and corporate experience and in particular has expertise in financial and operational restructuring. Mr. Fisher is currently the Managing Director of DMC Corporate Pty Ltd. and has previously held the position of CEO of Pental Limited.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDT:AU A$0.36 AUD +0.01

IDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDT.
View Industry Companies

Industry Analysis


Industry Average

Valuation IDT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDT AUSTRALIA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at